Collaborative Research and Development Agreements - Narrative (Details) - USD ($)			1 Months Ended	3 Months Ended		9 Months Ended
	Nov. 24, 2023	Oct. 23, 2020	Mar. 31, 2014	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Collaboration revenue				$ 30,017,000	$ 3,318,000	$ 48,167,000	$ 8,152,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab)
Disaggregation of Revenue [Line Items]
Collaboration revenue					0	0	0
GSK | GlaxoSmithKline Collaboration
Disaggregation of Revenue [Line Items]
Agreement term following first commercial sale or expiration of the last to expire patent		12 years
GSK | GlaxoSmithKline Collaboration | Minimum
Disaggregation of Revenue [Line Items]
Royalty percent on net sales			4.00%
GSK | GlaxoSmithKline Collaboration | Maximum
Disaggregation of Revenue [Line Items]
Royalty percent on net sales			8.00%
GSK | Royalties
Disaggregation of Revenue [Line Items]
Collaboration revenue				15,000,000	3,300,000	33,200,000	8,200,000
GSK | Royalty Agreement, Up To $1.0 billion | Anti-PD-1 (Jemperli/Dostarlimab)
Disaggregation of Revenue [Line Items]
Royalty percent on net sales		8.00%
Net sales royalty		$ 1,000,000,000
GSK | Royalty Agreement, Above $1.0 billion | Minimum | Anti-PD-1 (Jemperli/Dostarlimab)
Disaggregation of Revenue [Line Items]
Royalty percent on net sales		12.00%
GSK | Royalty Agreement, Above $1.0 billion | Maximum | Anti-PD-1 (Jemperli/Dostarlimab)
Disaggregation of Revenue [Line Items]
Royalty percent on net sales		25.00%
Net sales royalty		$ 1,000,000,000
GSK | Jemperli Royalty Monetization Agreement
Disaggregation of Revenue [Line Items]
Collaboration revenue				13,800,000	2,500,000	30,100,000	5,800,000
Annual sales milestone threshold						250,000,000
GSK | Zejula Royalty Monetization Agreement
Disaggregation of Revenue [Line Items]
Collaboration revenue				1,200,000	800,000	3,100,000	2,400,000
GSK | Zejula revenue prior to the Zejula Royalty Monetization Agreement
Disaggregation of Revenue [Line Items]
Collaboration revenue					$ 800,000		$ 2,400,000
GSK | First commercial sales milestone | Anti-PD-1 (Jemperli/Dostarlimab)
Disaggregation of Revenue [Line Items]
Collaboration revenue				15,000,000		15,000,000
Centessa Pharmaceuticals (UK) Limited (Centessa) | GlaxoSmithKline Collaboration
Disaggregation of Revenue [Line Items]
Potential future payments	$ 10,000,000			$ 10,000,000		$ 10,000,000
Centessa Pharmaceuticals (UK) Limited (Centessa) | GlaxoSmithKline Collaboration | License Agreement, Centessa Pharmaceuticals (UK) Limited
Disaggregation of Revenue [Line Items]
Cash payment	4,000,000
Reimbursement	3,000,000
Transaction costs incurred	300,000
Total transferred	$ 7,300,000